Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07635095 · ClinicalTrials.gov registry record · Phase 1
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
A Phase 1 study, sponsored by Astria Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07635095 is a Phase 1 study that is actively recruiting participants, run by Astria Therapeutics. The registered enrollment target is 180 participants.
The verdict
NCT07635095, a Phase 1 study, is actively recruiting participants, sponsored by Astria Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare two different presentations (vial and syringe versus autoinjector) of navenibart in healthy adult volunteers. The main questions it aims to answer are: * Do these presentations lead to similar drug concentrations in the blood? * Do these presentations lead to similar safety and tolerability? Researchers will compare the drug concentrations and safety profile of each group to determine if they are similar. Participants will: * Receive one dose of navenibart with either the vial and syringe or the autoinjector. * Stay in the clinic beginning one day prior to dosing through 2 days after dosing. * Return to the clinic for approximately 9 additional non-residential visits. * Complete medical and other testing, including blood draws.
Interventions
- COMBINATION_PRODUCT Autoinjector
- DRUG Vial and syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07635095
The ClinicalTrials.gov registry entry for NCT07635095 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astria Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Autoinjector is the first listed.
NCT07635095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07635095 about?
NCT07635095 is a clinical study titled "A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants". The goal of this clinical trial is to compare two different presentations (vial and syringe versus autoinjector) of navenibart in healthy adult volunteers. The main questions it aims to answer are: * Do these presentations lead to similar drug concentrations in the blood? * Do these presentations l...
What is the current status of trial NCT07635095?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-04-21. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07635095?
The interventions under investigation include: Autoinjector (COMBINATION_PRODUCT), Vial and syringe (DRUG).
Who is sponsoring clinical trial NCT07635095?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.